Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Debt-to-Equity : 0.78 (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Debt-to-Equity?

Biocytogen Pharmaceuticals (Beijing) Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €31.6 Mil. Biocytogen Pharmaceuticals (Beijing) Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €42.1 Mil. Biocytogen Pharmaceuticals (Beijing) Co's Total Stockholders Equity for the quarter that ended in Jun. 2024 was €94.7 Mil. Biocytogen Pharmaceuticals (Beijing) Co's debt to equity for the quarter that ended in Jun. 2024 was 0.78.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity or its related term are showing as below:

FRA:I54' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.36 Max: 0.78
Current: 0.78

During the past 4 years, the highest Debt-to-Equity Ratio of Biocytogen Pharmaceuticals (Beijing) Co was 0.78. The lowest was 0.06. And the median was 0.36.

FRA:I54's Debt-to-Equity is ranked worse than
82.99% of 1023 companies
in the Biotechnology industry
Industry Median: 0.14 vs FRA:I54: 0.78

Biocytogen Pharmaceuticals (Beijing) Co Debt-to-Equity Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Debt-to-Equity Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.06

0.07

0.36

0.69

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial			0.15	0.36	0.49	0.69	0.78

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity falls into.

Biocytogen Pharmaceuticals (Beijing) Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biocytogen Pharmaceuticals (Beijing) Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(26.096	+	43.782)	/	100.93
	=	0.69

Biocytogen Pharmaceuticals (Beijing) Co's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(31.59	+	42.073)	/	94.721
	=	0.78

Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biocytogen Pharmaceuticals (Beijing) Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

02315:Hong Kong

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines